MING-SHENG LEE, M.D.
Medical Practice at Holcombe Blvd, Houston, TX
License number
Texas H3486
Category
Medical Practice
Type
Hematology
Address
Address
1515 Holcombe Blvd, Houston, TX 77030
Phone
(713) 792-6161
(713) 792-2991
(713) 792-2991
Professional information
See more information about MING-SHENG LEE at trustoria.com
Dr. Ming-Sheng Lee, Sugar Land TX - MD (Doctor of Medicine)
Dr. Ming-Sheng Lee, Sugar Land TX - MD (Doctor of Medicine)
Age:
49
Address:
2702 Plantation Trl, Sugar Land 77478
Hospitals:
2702 Plantation Trl, Sugar Land 77478
The University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston 77030
The University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd, Houston 77030
Education:
Medical Schools
Taipei Medical College
Taipei Medical College
Ming-Sheng S Lee, Houston TX
Ming-Sheng S Lee, Houston TX
Specialties:
Hematologist
Address:
1515 Holcombe Blvd, Houston, TX 77030
6550 Corporate Dr, Houston, TX 77036
6550 Corporate Dr, Houston, TX 77036
Detection Of Minimal Numbers Of Neoplastic Cells Carrying Dna Translocations By Dna Sequence Amplification
Detection Of Minimal Numbers Of Neoplastic Cells Carrying Dna Translocations By Dna Sequence Amplification
US Patent:
5024934, Jun 18, 1991
Filed:
Mar 14, 1988
Appl. No.:
7/167585
Inventors:
Ming-Sheng Lee - Houston TX
Assignee:
The Board of Regents, The University of Texas System - Austin TX
International Classification:
C12Q 168, C07H 1512, C12N 1500
US Classification:
435 6
Abstract:
The present invention related to a sensitive method of detecting t(14;18) translocations arising from variable breakpoints in the J-region of the immunoglobulin heavy chain locus on chromosome 14. These breakpoints are typical abnormalities of human follicular lymphomas. In particular, the invention utilizes a sequence amplification by polymerase chain reaction in which primers are synthesized which are so designed that one primer will always flank the breakpoint in the J-region regardless of variation in the breakpoint. Consequently, the invention is a highly sensitive tool to detect minimal residual cells carrying the t(14;18) and has potential to identify patients with subclinical disease.
Detection Of Genomic Abnormalities With Unique Aberrant Gene Transcripts
Detection Of Genomic Abnormalities With Unique Aberrant Gene Transcripts
US Patent:
4999290, Mar 12, 1991
Filed:
Mar 31, 1988
Appl. No.:
7/175833
Inventors:
Ming-Sheng Lee - Houston TX
Assignee:
The Board of Regents, The University of Texas System - Austin TX
International Classification:
C12Q 168, C07H 1512, C12N 1500
US Classification:
435 6
Abstract:
The present invention involves a method for detecting the unique aberrant gene transcripts of a targeted cellular genomic abnormality in a tissue sample. This method comprises a series of steps. Initially, total cellular RNA or m-RNA is preferred from the tissue sample to be analyzed for the presence of a genomic abnormality. The total cellular RNA or m-RNA is then mixed with at least one synthetic DNA oligonucleotide complementary to the unique RNA sequence of the targeted cellular genomic abnormality being detected. The mixing is under conditions facilitating formation of double stranded DNA-RNA heteroduplexes when a strand of synthetic DNA oligonucleotide is complementary to an RNA strand obtained from the tissue sample. The conditions are those such as time, salt concentration, temperature and pH 10. The synthetic DNA oligonucleotide is preferably about several hundred nucleotides in length, more preferably about 60 to about 150 nucleotides in length.